Standard-of-Care

Category

UCLA Investigators Lead Study of Novartis’ Ribociclib Significantly Improves Overall Survival for Aggressive Breast Cancer

UCLA investigators helped lead a study that found by adding Novartis’ ribociclib, a targeted therapy drug, to standard hormone therapy, they can significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer....

Pin It on Pinterest